GlobeNewswire

Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction

Share

PRESS RELEASE

January 25, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2 million) in an upfront payment resulting from the now completed acquisition of Cadent Therapeutics by a third party. Saniona holds an ownership stake of approximately 3% in Cadent Therapeutics resulting from Cadent’s previous acquisition of the Saniona spin-out Ataxion, which was created to leverage Saniona’s ion channel expertise for the treatment of movement disorders. Saniona previously announced the planned acquisition and its ownership stake in December 2020.

“Saniona has developed a robust, proprietary drug discovery engine focused on ion channels, a rare scientifically validated drug class that remains significantly untapped,” said Jørgen Drejer, Chief Scientific Officer of Saniona. “It is gratifying to see our ion channel programs create value, and the funding that Saniona received from the Cadent transaction will be beneficial as we continue to advance our own, internal programs for the treatment of rare diseases.”

Following the closing of the acquisition of Cadent Therapeutics by Novartis, Saniona received an upfront payment of approximately USD $2.9 million (SEK 24.2 million), after giving effect to preferred stock preferences and the satisfaction of transaction costs and other closing conditions. Saniona may receive additional contingent consideration upon the achievement of future milestones. In connection with Saniona’s license agreement with Cadent, Saniona is also entitled to receive royalties on any potential products developed and commercialized from the SK ion channel (small conductance, calcium-activated potassium ion channel) program that originated with Ataxion, including CAD-1883, a first-in-class selective positive allosteric modulator of SK ion channels that Cadent has advanced into Phase 2 clinical trials and which may have potential in movement disorders. 

Saniona has been a pioneer in the field of ion channels since its founding in 2011, and several members of the Saniona scientific team have been working in this field for more than 20 years. Since its inception, Saniona has out-licensed or spun-out multiple ion channel programs. Ataxion was established in 2013 by Saniona and Atlas Venture Inc. with the aim of developing Saniona's research on SK ion channels for movement disorders. In 2017, Ataxion was acquired by Luc Therapeutics, which later changed its name to Cadent Therapeutics.

For more information, please contact

Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on January 25, 2021.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States4.3.2021 22:00:00 CETPress release

► Publication of positive topline results from the NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH and decision to move into pivotal Phase III development ► Breakthrough Therapy Designation granted to lanifibranor in NASH by the U.S. Food and Drug Administration (FDA) ► Finalization of Phase III clinical trial design with lanifibranor in NASH following end-of-phase II meeting with the FDA and receipt of Scientific Advice letter from the European Medicines Agency (EMA) ► Expansion into the United States with appointment of Dr. Michael Cooreman, M.D., as Chief Medical Officer and opening of U.S. subsidiary ► Announcement of timeline for Phase III clinical trial evaluating lanifibranor in NASH ► Confirmation by the FDA that the toxicology package regarding lanifibranor is complete and acceptable to support the filing of a New Drug Application (NDA) for the treatment of NASH and improvement of liver fibrosis ► Completion of World Health Organization’s (WHO) International No

Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report4.3.2021 22:00:00 CETPress release

Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report Nokia Corporation Stock Exchange Release March 4, 2021 at 23:00 EET Nokia has filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission and published its Nokia in 2020 Annual Report. Espoo, Finland – Nokia has today filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission. Additionally, Nokia has published its Nokia in 2020 Annual Report, which includes audited financial statements, the annual review by the Board of Directors, Nokia’s corporate governance statement and the Remuneration Report for the governing bodies for 2020. The Annual Report on Form 20-F and Nokia in 2020 Annual Report will be available in PDF format at www.nokia.com/about-us/investors/reports-filings, along with Nokia’s past quarterly and annual financial reports. Shareholders may request a hard copy of the reports free of charge through Nok

Appellate Court Hands Momentous Victory to TriMax Over Wickfire4.3.2021 21:35:30 CETPress release

The Fifth Circuit Court of Appeals issued a decisive ruling that TriMax Media committed no legal violations against Wickfire, L.L.C., while recognizing a jury’s finding that Wickfire intentionally interfered with TriMax’s business. DALLAS, March 04, 2021 (GLOBE NEWSWIRE) -- After seven years of litigation, TriMax has triumphed over Wickfire. On February 26, 2021, an Appellate Court issued a paramount ruling that Wickfire lacked any evidence to support its claims against TriMax. The decision was made in the United States Court of Appeals for the Fifth Circuit, Case Number 17-3043040. The Appellate Court’s ruling reversed all monetary damages previously awarded to Wickfire. The lawsuit, originally before the Western District of Texas, Case No. 14-CV-34, centered around Google AdWords Auctions, an online-auction platform where companies like TriMax and Wickfire compete for advertising space. Wickfire asserted innumerable claims against TriMax, but as to each one, Wickfire ultimately faile

Informa Markets Drives Economic Recovery with Safe and Successful Return to the Show Floor4.3.2021 20:52:58 CETPress release

Informa Markets makes a customer-driven return to live events, driving economic recovery, connection and innovation through a collaborative and foundational approach to safety ORLANDO, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- As industries and economies around the world look for opportunities to rebuild business in the wake of the COVID-19 pandemic, Informa Markets, a global organizer who creates platforms for a wide range of industries to trade, connect and grow, launched MAGIC Pop-Up Orlando from February 9-11 at the Orange County Convention Center. The ‘Pop-Up’, a smaller scale regional version of their keystone fashion event which typically takes place twice-yearly in Las Vegas, Nevada was a comprehensive ‘one-stop-shop’ opportunity for various segments of the fashion industry, one of the many industries hit hard by the pandemic’s devastating economic impact, to discover new brands, safely network with like-minded retailers, and generate much-needed revenue. Informa Markets Fashion

CoinShares announces outcome of offering in connection with its intended listing on Nasdaq First North Growth Market4.3.2021 20:30:00 CETPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Saint Helier, JERSEY, 4 March, 2021 The subscription period for shares in the initial public offering (the “Offering”) from CoinShares International Limited (“CoinShares” or the “Company”) ended Tuesday, 2 March, 2021. The outcome of the Offering shows that the Offering was subscribed to 447% and that the Company will receive proceeds of SEK 151.1 million before issue costs. The Offering of SEK 151.1 million was covered by subscription commitments of SEK 125.5 million, corresponding to 83% of the total